Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B

Next Previous
X
Search
Trial Profile

Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etranacogene dezaparvovec (Primary)
  • Indications Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms HOPE-B
  • Sponsors CSL Behring; uniQure

    • Most Recent Events

    • 07 Feb 2025 Four year results presented in the CSL Behring Media Release.
    • 16 Jul 2024 According to a CSL Behring media release, company announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) recommended public drug plan reimbursement for HEMGENIX (etranacogene dezaparvovec) for the treatment of eligible adults with hemophilia B, recommendation is based on results from the ongoing Phase III HOPE-B trial.
    • 04 Jul 2024 According to a CSL media release, Australia's Therapeutic Goods Administration (TGA) has granted provisional registration for HEMGENIX (etranacogene dezaparvovec) for treatment of adults with haemophilia B (congenital factor IX deficiency), without a history of factor IX inhibitors, who: currently use factor IX prophylaxis therapy, or have current or historical life-threatening haemorrhage, or repeated, serious spontaneous bleeding episodes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top